Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Association of T3/T4 ratio with inflammatory indicators and all-cause mortality in stroke survivors.
Front Endocrinol (Lausanne)
January 2025
Department of Neurosurgery, Huzhou Central Hospital, Huzhou, China.
Background: Abnormal thyroid hormone levels may occur in critical illness, which may have an interactive relationship with inflammatory reaction. At present, the relationship between triiodothyronine (T3)/thyroxine (T4) ratio and inflammatory indicators and all-cause mortality of stroke survivors is still unclear.
Methods: We obtained the relevant data of the respondents from 2007 to 2012 through the National Health and Nutrition Examination Survey (NHANES) database for statistical analysis.
THE SERUM CREATININE TO CYSTATIN RATIO IN THYROTOXICOSIS PATIENTS: A CASE-CONTROL STUDY.
Acta Endocrinol (Buchar)
January 2025
Zigong Fourth People's Hospital, Department of Endocrinology, Zigong, Sichuan, China.
Context: Previous studies have demonstrated a correlation between creatinine and cystatin levels and thyroid disorders.
Objective: To further investigate the diagnostic value of serum creatinine to cystatin C ratio in the diagnosis of thyrotoxicosis.
Design: One hundred eighty four thyrotoxicosis patients and 406 healthy controls were enrolled.
Treatment of Primary Hypothyroidism by Slow-Release Liothyronine Monotherapy.
Endocr Metab Immune Disord Drug Targets
January 2025
Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Background: Combination therapy with levothyroxine (L-T4) and slow-release T3 (SRT3) in the treatment of hypothyroidism results in a normal triiodothyronine/thyroxine (T3/T4) ratio above that of L-T4 monotherapy. No clinical study has been reported with SRT3 monotherapy for hypothyroidism.
Methods: This study was conducted in two parts.
Association between clinical activity score and serum sPD-1 and sPD-L1 levels during systemic glucocorticoid treatment for active moderate-to-severe thyroid eye disease.
Cytokine
January 2025
Collegium Medicum, Jan Kochanowski University in Kielce, 25-317 Kielce, Poland; Department of Endocrinology, Holy Cross Cancer Center, 25-734 Kielce, Poland.
Background: CD4+ T lymphocytes are key immune cells involved in orbital inflammation in thyroid eye disease (TED). Inhibition of their activity is important in treatment of TED, but effective drugs targeting these cells are lacking. The programmed cell death-1/programmed cell death ligand-1 pathway has been implicated in several T-cell-mediated diseases.
View Article and Find Full Text PDFTriiodothyronine treatment in mice improves stroke outcome and reduces blood-brain barrier damage.
Eur Thyroid J
January 2025
F Langhauser, Neurology, University Hospital Essen Department of Neurology, Essen, Germany.
Objective Thyroid hormones (TH) control a variety of processes in the central nervous system and influence its response to different stimuli, such as ischemic stroke. Post-stroke administration of 3,3',5-triiodo-L-thyronine (T3) has been reported to substantially improve outcomes, but the optimal dosage and time window remain elusive. Methods Stroke was induced in mice by transient middle cerebral artery occlusion (tMCAO) and T3 was administered at different doses and time points before and after stroke.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!